Is SCPX's EPS trend positive for long-term investors?

**Scorpius Holdings' (SCPX) EPS trend does not appear positive for long-term investors**, and here's why:

1. **Consistent Negative EPS**: SCPX has experienced negative EPS in all the reported periods: Q1 2024 (-$0.16), Q2 2024 (-$26.98), and Q3 2024 (-$1.43). This consistency is a red flag for investors as it indicates a company struggling to generate profit.

|code|Ticker|Name|Date|Diluted EPS YoY|Diluted EPS|market_code|
|---|---|---|---|---|---|---|
|SCPX|SCPX.A|Scorpius Holdings|2024 Q1|67.3469387755102|-0.16|170|
|SCPX|SCPX.A|Scorpius Holdings|2024 Q2|74.70704040498734|-26.98|170|
|SCPX|SCPX.A|Scorpius Holdings|2024 Q3|98.58163062884347|-1.43|170|

2. **Increasing Revenue**: While revenue has increased over the same periods (+$3.5 million in Q1, +$0.8 million in Q2, and +$0.9 million in Q3), the growth in revenue has not translated into profitability. This could be due to high operational costs or inefficiencies that are eating into the company's potential profits.
3. **Cash Flow and Funding Challenges**: The company's cash position has been precarious, with limited cash reserves and short-term investments. This was evident as of March 31, 2024, with only $1.7 million in cash and short-term investments. By December 20, 2024, the cash dropped to $1.8 million, indicating a critical need for additional capital. The company's urgency for funding is underscored by its exploration of various financing options, including equity and debt financings, equipment sale leasebacks, and potential partnerships.
4. **Market Performance and Stock Price**: The company's stock performance reflects the market's concerns. With a dramatic 99.67% decline over the past year, the stock price is likely under pressure due to the negative earnings and the company's financial distress.
5. **Strategic Positioning and Future Prospects**: Despite the challenges, the company is positioning itself to lead in biologic and cell therapy markets. However, the current financial state and the need for additional capital raise questions about the company's ability to execute on this strategic vision and whether investors can benefit from it in the near term.

In conclusion, while SCPX shows signs of growth in revenue, the negative and increasingly large EPS figures, combined with cash flow challenges and funding needs, suggest a risky investment proposition for long-term investors. The company's strategic positioning may offer potential in the future, but it is overshadowed by the immediate financial struggles. Investors should exercise caution and consider the high risks before investing in SCPX.